GlassScriptPhysician profile
Joy Gao
NPI 1659042521
$28,947.61
in general payments reported to CMS, 2019-2025
67 companies · $8,480 in 2025
The $8,480 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $535 · 2022: $5,424 · 2023: $5,829 · 2024: $8,680 · 2025: $8,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K · Education: $60.19 · Travel and Lodging: $5.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22,923.39 |
| Education | $60.19 |
| Travel and Lodging | $5.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $4,310.71 | 2022-2025 | Fintepla, Briviact, Zilbrysq |
| Abbvie INC. | $2,273.15 | 2021-2025 | |
| Neurelis, INC. | $1,339.28 | 2021-2025 | Valtoco |
| Alnylam Pharmaceuticals INC. | $1,276.42 | 2022-2025 | Amvuttra, Onpattro |
| Biogen, INC. | $1,240.81 | 2022-2025 | Vumerity, Leqembi, Tysabri |
| Livanova USA, INC. | $1,181.12 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Lundbeck LLC | $1,085.13 | 2022-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $1,043.52 | 2021-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $987.77 | 2021-2025 | Kisunla, Amyvid, Reyvow |
| Sk Life Science, INC. | $963.07 | 2022-2025 | Xcopri |
| Eisai INC. | $890.57 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $848.36 | 2023-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $680.43 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $644.43 | 2022-2025 | Crexont, Rytary |
| Janssen Pharmaceuticals, INC | $614.19 | 2022-2024 | Xarelto, Ponvory |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $580.43 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Mdd US Operations, LLC | $562.01 | 2023-2025 | Gocovri, Gocovri, Qelbree |
| Acadia Pharmaceuticals INC | $539.99 | 2022-2025 | Nuplazid |
| Amgen INC. | $482.74 | 2022-2025 | Uplizna |
| Genentech USA, INC. | $479.29 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Takeda Pharmaceuticals U.S.A., INC. | $455.23 | 2022-2025 | Hyqvia |
| Biohaven Pharmaceutical Holding Company LTD. | $375.66 | 2022 | |
| Pfizer INC. | $370.97 | 2023-2025 | |
| Emd Serono, INC. | $369.83 | 2022-2025 | Mavenclad, Mavenclad |
| Kyowa Kirin, INC. | $367.00 | 2021-2025 | Nourianz |
| Horizon Therapeutics Plc | $322.30 | 2022-2023 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $307.46 | 2023-2025 | Rexulti |
| Grifols USA, LLC | $291.60 | 2023-2025 | Gamunex-C |
| Tg Therapeutics, INC. | $227.53 | 2024-2025 | |
| Tanabe Pharma America, INC. | $215.59 | 2022-2025 | Radicava |
| Banner Life Sciences, LLC | $203.61 | 2022-2024 | |
| Janssen Biotech, INC. | $198.37 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $190.69 | 2022-2024 | Andexxa, Wainua |
| Jazz Pharmaceuticals INC. | $190.09 | 2022-2023 | |
| Catalyst Pharmaceuticals, INC. | $182.37 | 2021-2024 | Fycompa, Firdapse |
| Axsome Therapeutics, INC. | $170.11 | 2025 | Symbravo |
| Boston Scientific Corporation | $139.46 | 2022 | |
| Genentech, INC. | $134.93 | 2024 | Ocrevus |
| Sumitomo Pharma America, INC. | $129.16 | 2023-2024 | Aptiom |
| Genzyme Corporation | $128.96 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $127.07 | 2024-2025 | Inbrija, Xeomin |
| Novartis Pharmaceuticals Corporation | $126.91 | 2023-2025 | |
| Exact Sciences Corporation | $124.99 | 2024 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $124.49 | 2023-2025 | Ponvory, Hetlioz, Fanapt |
| Daiichi Sankyo INC. | $123.67 | 2023 | Injectafer |
| Csl Behring | $121.05 | 2023-2025 | Hizentra |
| Almatica Pharma LLC | $116.38 | 2022-2023 | Gralise |
| Aucta Pharmaceuticals, INC. | $113.44 | 2025 | Motpoly Xr |
| Amarin Pharma, INC. | $111.45 | 2024 | |
| Scynexis, INC. | $111.07 | 2022 | |
| Phathom Pharmaceuticals, INC. | $110.57 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $101.53 | 2022 | |
| Celgene Corporation | $86.40 | 2025 | Zeposia |
| Acorda Therapeutics, INC | $69.84 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $51.70 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $42.63 | 2024 | |
| Novo Nordisk INC | $41.80 | 2022-2023 | Rybelsus, Ozempic |
| Avion Pharmaceuticals | $40.86 | 2023 | Dhivy |
| Ge Healthcare | $33.41 | 2025 | |
| Chiesi USA, INC. | $27.47 | 2022 | |
| Medtronic, INC. | $27.30 | 2023 | Linq II |
| Impel Pharmaceuticals INC. | $24.99 | 2023 | Trudhesa |
| Microtransponder, INC. | $23.89 | 2025 | |
| Octapharma USA, INC. | $22.29 | 2024 | Panzyga |
| Arbor Pharmaceuticals, INC. | $18.69 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.80 | 2023 | Horizant |
| Supernus Pharmaceuticals, INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Gao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.